Premium Reports
Quality Management 2021
New

Quality Management 2021
Progress and Innovations

January 28, 2021 | Read Time: 7  minutes

Current Time Inside Cache Tag Helper: 3/3/2021 2:33:20 AM and Model.reportId = 1648

The COVID-19 pandemic has brought into sharp relief the need for quality management innovations, especially around patient safety and risk. Previous KLAS research showed many vendors had grown stagnant in their tool development. This study draws on insights from general users and advanced users to show how vendors are innovating in the market and helping provider organizations advance their quality management efforts. For the purposes of this research, quality management includes three areas: (1) quality and regulatory reporting, (2) performance improvement and benchmarking, and (3) patient safety and risk.

Healthcare Providers,
Want to see full details?

Not a Provider, contact us for pricing details.

Current Time Inside Cache Tag Helper: 3/3/2021 2:33:20 AM and Model.reportId = 1648

Key Findings:

  1. Conduent General Customer Base Reports Functionality Gaps That Hinder Outcomes; IBM Stagnant
  2. Medisolv Updates & Proactivity Drive Outcomes; Nuance Clients Satisfied, though See Less Innovation
  3. Premier, Vizient Drive Outcomes for Advanced Users; For General Users, Premier’s Cost Inhibits New Technology Adoption, Vizient Cumbersome
  4. RLDatix M&A Activity Has Customers Uncertain but Hopeful
  5. Advanced Users See Initial Positive Outcomes from Riskonnect, Origami Risk, VigiLanz
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2021 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.